编辑 杨娟娟 新京报贝壳财经讯 11月7日，据同创伟业官方公众号消息，智能气动领域企业阿尔赛克完成数千万Pre- A轮融资。本轮融资由同创伟业与明势创投联合领投，相城金控跟投。此次融资将重点用于产品深化正 向研发投入及加速市场布局。 ...

Core Points - The Tesla 2025 Annual Shareholder Meeting took place on November 6, where over 75% of shareholders approved Elon Musk's compensation plan, which includes stock options amounting to approximately 12% of the current total shares [1][2] - Musk emphasized the integration of sustainable energy and AI technology as a key focus for Tesla's future development [1] - Tesla's stock price closed at $235.2, reflecting a 1.69% increase in after-hours trading, but market reactions were generally lukewarm due to concerns over the company's performance [1][8] Compensation Plan Details - Musk's compensation plan involves unlocking 423.7 million shares of restricted stock over 10 years, with a potential value of around $1 trillion based on current stock prices [2][4] - The plan includes market capitalization targets ranging from $2 trillion to $8.5 trillion, alongside operational metrics such as delivering 20 million vehicles and achieving specific EBITDA targets [2][4] Shareholder Reactions - Some shareholders, including Norway's sovereign wealth fund, expressed concerns over the high dilution of shares and the lack of short-term verifiable performance metrics [5] - Proxy advisory firms ISS and GlassLewis recommended opposing the plan, citing insufficient rigor in the performance-linked compensation structure [5] - Support for the plan came from Tesla's board, which argued that Musk's leadership is crucial for the company's strategic direction and technological advancements [5] Financial Performance - Tesla's Q3 financial results showed a net profit of $1.373 billion, a 37% year-over-year decline, marking the third consecutive quarterly drop [1][8] - The company's total revenue for Q3 was $28.095 billion, a 12% increase year-over-year, but the automotive business faced challenges with a gross margin of 15.4% when excluding regulatory credits [8] - Vehicle deliveries for the first three quarters of 2025 totaled 1.217 million, reflecting only a 3.26% year-over-year growth [8] Technological Developments - Musk indicated that the mass production of the third-generation Optimus robot will not commence until the end of 2026, raising questions about Tesla's technological leadership [9] - The rollout of Tesla's Full Self-Driving (FSD) technology remains delayed, with ongoing discussions with regulatory bodies in various markets [9] - Concerns have been raised by investors regarding the long-term performance of Tesla in relation to the ambitious compensation plan [9]

Core Insights - EssilorLuxottica celebrates its 30th anniversary in China and showcases multiple new products at the China International Import Expo, focusing on myopia management for children and adolescents, adult vision health, and wearable devices [1] - The company collaborates with partners to launch initiatives in consumer insights, industry standards, and public welfare education [1] - The 2026 edition of the National Vision Health Report is initiated, aiming to deepen discussions on myopia prevention and expand to "lifecycle eye health" [1] Group 1 - EssilorLuxottica supports the Shanghai Eye Disease Prevention Center in launching the national health industry standard "Guidelines for Graded and Classified Prevention and Treatment of Myopia in Children and Adolescents" [2] - The company provided over 8,000 lenses for a school-based myopia intervention project, which is part of Shanghai's public health system enhancement plan [2] - The new guidelines will promote a graded and classified approach to myopia management, emphasizing early intervention [2] Group 2 - EssilorLuxottica releases a digital version of "Our Eyes," developed in collaboration with leading optometry experts, to meet the educational needs of the digital age [3] - The digital version incorporates the latest knowledge from the "Myopia Prevention and Control White Paper (2025)" and uses animated videos and educational materials to raise awareness among children and adolescents [3] - The company also showcases the innovative Essilor Star Control smart glasses, which feature a monitoring module to help children meet recommended wearing times for effective myopia management [3]

Core Insights - The China International Import Expo (CIIE) is increasingly recognized as a platform for promoting international trade cooperation and mutual benefits, contributing positively to both the Chinese and global economies [1] Company Highlights - Amway, celebrating 30 years in China, showcased its health products and services at the CIIE, addressing the diverse health needs of the public through innovative solutions and research achievements [2] - Amway's Chairman and President, Yu Fang, emphasized the expo's role in enhancing global companies' confidence in investing in China, positioning the country as a strategic market for Amway [4] - Amway launched a new product, a multi-vitamin and mineral powder called "Little Gold Powder," aimed at addressing nutritional imbalances in the Chinese diet, marking it as the first "blue hat" multi-nutrient powder in the market [5] Product Innovations - Amway presented a range of anti-aging products focused on improving healthspan, utilizing plant-based nutrients to enhance quality of life [7] - The company also highlighted products targeting metabolic health, dietary balance, and weight management, showcasing a comprehensive approach to health solutions [8] - Amway's Nutrilite brand is centered on plant nutrients, with significant investments in research and development, including a plant research center in Wuxi and the integration of AI technology for product development [8][10] Investment and Growth Strategy - Amway has initiated a five-year investment plan of 2.1 billion yuan (approximately 300 million USD) from 2023 to 2027, focusing on upgrading production facilities, digital infrastructure, and enhancing research capabilities [13] - The company aims to strengthen its supply chain and innovation capabilities in China, reinforcing its position as a strategic growth engine [14] - Amway's long-term commitment to the Chinese market is evident, with a focus on aligning its development with national strategies for health and well-being [12][14]

Core Viewpoint - Kaisi China announced the upgrade of the "Marco Polo Program" to version 3.0 during the 8th China International Import Expo, marking a significant milestone in Sino-Italian cooperation and showcasing innovative pharmaceutical products [1] Group 1: Strategic Partnerships - Kaisi China signed a strategic cooperation agreement with JD Health, enabling the full line of respiratory products to be available on the platform, focusing on disease education, online consultations, and smart chronic disease management [2] - Kaisi China upgraded its strategic cooperation with Shanghai Pharmaceutical Cloud Health, allowing its respiratory health products to be integrated into "Yiyao Pharmacy" for comprehensive outpatient services [2] - A memorandum of cooperation was signed with the China Rare Disease Alliance to enhance rare disease management and establish standardized treatment systems [2] Group 2: Product Innovations - In the "CARE" specialty treatment area, Kaisi China showcased its key products for premature infants, including porcine lung surfactant injection and caffeine citrate injection [3] - The "AIR" respiratory health sector introduced a new inhalation powder for asthma patients, providing a new treatment option [3] - Kaisi China presented nine innovative rare disease drugs at the expo, targeting eleven rare diseases, with some being the only treatment options available [3] - The first drug approved for treating wounds related to certain genetic skin disorders was highlighted, benefiting patients in China [3] Group 3: Academic and Professional Development - Kaisi China launched the "Everest Project" to promote high-level academic exchanges and cooperation among top respiratory experts, enhancing medical education and patient management [3]

新京报讯（记者王卡拉）11月6日，勃林格殷格翰携手跨领域专家，在本届进博会展台上举办了"赋能启 航 共筑健康"主题活动，共同探讨我国代谢相关脂肪性肝炎（简称MASH）防治的中国方案。与会嘉宾 围绕疾病认知、规范化诊疗、经济负担、创新药物可及等话题展开深入交流，共同倡议开展针对中国人 群代谢相关脂肪性肝炎疾病负担研究，助力构建更完善的MASH诊疗与疾病管理体系。 MASH是一种与代谢紊乱密切相关的肝脏疾病。近年来，随着肥胖、糖尿病等代谢性疾病患病率的攀 升，MASH的患病率也显著上升，逐渐成为全球范围内重大的健康挑战之一，患者通常合并肥胖或糖尿 病等代谢疾病。相较全球其他国家，我国MASH疾病增长率仍处于较高水平。 面对MASH治疗的迫切临床需求，勃林格殷格翰正在加速推进旗下创新药物survodutide的研发进程。作 为一款胰高血糖素受体（GCGR）和胰高血糖素样肽-1受体（GLP-1R）双重激动剂，survodutide于2024 年6月获得国家药品监督管理局药品审评中心授予的"突破性治疗"认定，并已进入Ⅲ期临床试验阶段。 该药物有望为肥胖及代谢相关脂肪性肝炎患者提供全新的治疗选择。 如何推动MASH疾病的 ...

Core Insights - The sales of new energy vehicles (NEVs) in China have surged this year, leading to a significant influx of used NEVs into the trading market, driven by the "trade-in" policy for consumer goods [1] - The auction market for used cars has become a vital channel in the circulation system of used cars, with a reported 52.6% increase in auction transaction volume for NEVs in the first three quarters of the year, and an expected annual transaction value exceeding 10 billion yuan [1] - Used car dealers are leveraging auction platforms to source vehicles, reducing inventory turnover cycles to under 15 days, which is significantly lower than the industry average [1] - The auction model facilitates transactions without geographical limitations and efficiently matches supply and demand, allowing surplus vehicles from first- and second-tier cities to flow into the high-demand third- and fourth-tier cities and county markets, promoting tiered consumption of automobiles [1]

Core Viewpoint - WM Motor has signaled a potential revival with the re-launch of its "Xiao Wei" app and announcements of upcoming production plans, raising market interest in its restructuring efforts [1][4][5] Group 1: Company Developments - WM Motor announced the re-launch of the "Xiao Wei" app, which includes features like Bluetooth control and vehicle information synchronization, indicating a step towards operational recovery [4][5] - The company plans to hold a new car launch event by the end of November, which may provide updates on its product and service network [5] - After a two-year production halt, WM Motor aims to restart production by 2025, with a target of producing 10,000 to 20,000 vehicles annually, focusing on optimized models like EX5 and E5 [2][7] Group 2: Challenges Ahead - The company faces significant challenges in regaining brand trust, as many former customers reported issues with after-sales service and vehicle maintenance during the production halt [8] - Rebuilding the supply chain and sales channels is critical, as the existing supplier network has been disrupted, and many physical stores have closed [9] - WM Motor's research and development capabilities remain a concern, as it has historically relied on external partnerships for key technologies, which may hinder its competitiveness in a rapidly evolving market [9] - The competitive landscape for electric vehicles has intensified, with the top 10 manufacturers capturing nearly 80% of the market share, posing a challenge for WM Motor to carve out a niche [9]

Core Viewpoint - Pop Mart (09992.HK) is experiencing significant revenue growth, with a notable increase in both domestic and international markets, driven by the popularity of its LABUBU IP. Group 1: Financial Performance - In Q3 2025, overall revenue is expected to grow by 245% to 250% year-on-year, with domestic revenue increasing by 185% to 190% and international revenue rising by 365% to 370% [4] - For the first half of 2025, Pop Mart reported revenue of 13.88 billion yuan, a year-on-year increase of 204.4%, and an adjusted net profit of 4.71 billion yuan, up 362.8% [5] - The profit attributable to the company's owners reached 4.574 billion yuan, reflecting a year-on-year growth of 396.5% [5] Group 2: Channel Performance - In Q3, offline channel revenue grew by 130% to 135% year-on-year, while online channel revenue surged by 300% to 305% [5] - The success of the LABUBU brand has significantly contributed to the company's performance growth in 2025 [5] Group 3: Company Response - Pop Mart is actively addressing recent issues and has confirmed that it will not dismiss the employee involved in the situation [3]

Core Insights - Thunderbird Innovation has completed a multi-hundred million C-round financing led by CITIC Jinshi, with participation from CITIC Securities International Capital and CITIC Securities Investment, aimed at accelerating the development of AI+AR glasses technology and ecosystem [1] - The company was established in October 2021 and has positioned itself in the consumer-grade AR market, launching the lightweight AI shooting glasses V3 series and covering over 25 countries and regions globally [2]